NCT00924703
Phenylketonuria
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
All
16 Years to 55 Years
No
rAvPAL-PEG
Phase 2
Interventional
68
2010-01-13
2021-10-12
Aurora, Colorado, United States
Gainesville, Florida, United States
Chicago, Illinois, United States
Louisville, Kentucky, United States
Boston, Massachusetts, United States
Columbia, Missouri, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
Albany, New York, United States
New York, New York, United States
Portland, Oregon, United States
Pittsburgh, Pennsylvania, United States
Salt Lake City, Utah, United States
Milwaukee, Wisconsin, United States
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields